State of Viscosupplementation: 2026

---

Market Overview

The Current Landscape

The U.S. viscosupplementation market is valued at approximately $3.2-$3.5 billion annually as of 2026, with steady growth driven by an aging population, rising osteoarthritis prevalence, and increased awareness of non-surgical treatment options.

An estimated 2.5 million viscosupplementation procedures are performed annually in the United States. The majority are knee injections, though shoulder and hip applications continue to grow.

Major Brands in the Market

The viscosupplementation market remains competitive, with established brands and newer entrants:

Market Trends

Single-injection products are gaining share. The convenience of one visit versus three to five weekly appointments is driving a clear shift. Synvisc-One, Monovisc, Durolane, and Gel-One now account for an increasing percentage of the market. Patients prefer fewer office visits, and providers benefit from streamlined scheduling.

Non-avian products are growing. Products derived from bacterial fermentation (Euflexxa, Monovisc, Durolane, Orthovisc) eliminate the theoretical risk for patients with avian allergies. This is a selling point even though clinically significant allergic reactions remain rare.

Biosimilar and generic competition is emerging. Lower-cost alternatives like GenVisc 850 are putting pricing pressure on established brands, particularly in cost-sensitive institutional settings.

---

Key 2025-2026 Developments

BCBS Illinois Coverage Withdrawal

The most significant insurance development of 2025-2026 was Blue Cross Blue Shield of Illinois ending viscosupplementation coverage effective January 1, 2026. BCBS Illinois classified HA injections as “not medically necessary,” citing selected guideline reviews.

What this means in practice:

• BCBS Illinois commercial plan members lost coverage for HA injections
• Federal Employee Program members and government program participants are excluded from the change
• Patients with BCBS Illinois must now pay out of pocket, appeal the decision, or seek coverage through Medicare if eligible
• The decision has sparked concern about a potential domino effect among other BCBS affiliates, though no additional Blue Cross plans had announced similar changes as of March 2026

Why this matters: BCBS is the largest insurer in Illinois and one of the largest in the country. Their coverage decision could influence other private payers, even though it contradicts substantial peer-reviewed evidence.

For affected patients, we’ve published a detailed advocacy and appeal guide.

Arthrosamid: A New Category Enters

One of the most discussed developments in the joint injection space is Arthrosamid (polyacrylamide hydrogel), a non-HA injectable developed by Contura International. Unlike traditional viscosupplementation, Arthrosamid is designed to integrate into the synovial tissue and provide longer-lasting cushioning.

Current status (March 2026):

• Approved in Europe and several other markets
• FDA review process ongoing in the United States
• Published clinical data showing pain reduction at 2+ years post-injection in some studies
• Not yet available for general clinical use in the U.S.

What to watch: If FDA-approved, Arthrosamid would represent the first truly new mechanism of action in the injectable joint space in decades. Its longer duration could change the treatment calculus for patients currently getting HA injections every 6-12 months.

However, the long-term safety data is still limited. Patients should be cautious about clinics promoting non-FDA-approved injectable products or medical tourism for treatments not yet available domestically.

Anti-Cortisone Evidence Continues to Build

The evidence against long-term cortisone use for osteoarthritis continued to strengthen in 2025-2026:

• The landmark JAMA 2017 study showing cortisone-associated cartilage loss has been supported by additional longitudinal data
• Multiple professional societies have updated guidelines to limit cortisone injection frequency (typically no more than 3-4 per year per joint)
• A growing body of evidence suggests that repeated cortisone injections may accelerate osteoarthritis progression

The practical shift: More providers are moving toward a model where cortisone is used for short-term acute flares, while viscosupplementation is positioned as the medium-term maintenance treatment. This “cortisone for the crisis, HA for the long haul” approach is becoming standard practice in many orthopedic and pain management settings.

---

Research Highlights

Surgery Delay Data

The evidence that viscosupplementation can meaningfully delay knee replacement continues to grow:

• Studies tracking patients over 5+ years show HA injection users undergo knee replacement an average of 2-3 years later than matched controls
• The economic implications are significant: delaying one knee replacement by 3 years saves the healthcare system an estimated $15,000-$25,000 per patient when accounting for surgery costs, rehabilitation, and time off work
• For patients under 65, delaying surgery reduces revision risk since artificial joints have finite lifespans

Patient Satisfaction Outcomes

A recurring theme in 2025-2026 research: patient satisfaction metrics for viscosupplementation are consistently higher than clinical guideline recommendations might suggest.

• Patient-reported outcome data shows 65-75% of patients rate their HA injection experience positively
• Satisfaction correlates most strongly with realistic expectations and imaging-guided injection technique
• Patients receiving fluoroscopic or ultrasound-guided injections report higher satisfaction than those receiving blind injections

Opioid Reduction Evidence

In the context of the ongoing opioid epidemic, several studies have documented that viscosupplementation is associated with reduced opioid use in knee OA patients. This public health angle has strengthened the case for maintaining insurance coverage.

Quality-of-Life Studies

Randomized controlled trial data published in 2025 reinforced that HA injections provide meaningful quality-of-life improvements beyond pain scores alone. Measures of function, sleep quality, and psychological well-being all improved in treatment groups.

---

Insurance Landscape in 2026

Medicare: Stable Coverage

Medicare Part B continues to cover viscosupplementation for documented knee osteoarthritis. Key points for 2026:

• Coverage requires documented failure of conservative treatment (typically PT and/or oral medications)
• Imaging documentation of osteoarthritis (X-ray or MRI) is required
• Both single-injection and multi-injection products are covered
• Three key requirements remain unchanged: documented OA, failed conservative care, appropriate clinical indication
• Typical patient out-of-pocket cost: $100-$300 per treatment series after Medicare and supplemental coverage

Medicare’s continued coverage reflects their assessment that the evidence supports medical necessity for qualifying patients. This position has not changed despite the BCBS Illinois decision.

Private Insurance: Mixed Signals

The private insurance landscape in 2026 is fragmented:

The Prior Authorization Burden

Even where coverage exists, the administrative burden of prior authorization has increased. Many insurers now require:

• Documented X-ray evidence of OA
• Records of failed conservative treatment (typically 3+ months)
• Clinical justification letter from the treating physician
• Specific product selection aligned with insurer formularies

For guidance on navigating denials, see our insurance denial appeal guide.

---

Emerging Trends to Watch

1. Imaging Guidance Becoming Standard

The shift toward image-guided injections (ultrasound or fluoroscopy) is accelerating. While not yet universally required by insurers, the evidence increasingly supports guided injection for:

• Higher accuracy rates (studies show 20-30% of blind knee injections miss the joint space)
• Better clinical outcomes in comparative studies
• Patient confidence and satisfaction
• Reduced need for repeat injections due to missed placements

Some payers are beginning to consider separate reimbursement for imaging guidance, recognizing its value in improving outcomes.

2. Combination Protocols

The “one treatment at a time” model is giving way to multimodal approaches:

• HA + PT: The most evidence-supported combination
• HA + PRP: Some providers are experimenting with sequential or concurrent protocols, though evidence is early
• HA + weight loss programs: Increasingly recognized as synergistic
• HA + bracing: Mechanical support combined with lubrication supplementation

3. Shoulder and Hip Applications Growing

While knee OA remains the primary indication, HA injection use in other joints continues to expand:

• Shoulder OA: Growing evidence base supporting efficacy, particularly for patients who are not surgical candidates
• Hip OA: Less established than knee, but increasing clinical use, always requiring imaging guidance due to joint depth
• Ankle OA: Early research exploring HA for ankle arthritis

4. Patient Education and Shared Decision-Making

A notable trend: more practices are investing in patient education materials, shared decision-making tools, and outcomes tracking. This reflects a broader movement toward evidence-informed patient choice rather than physician-directed treatment.

5. Telehealth Integration

Follow-up visits, outcome monitoring, and treatment planning for viscosupplementation are increasingly handled via telehealth. While the injection itself requires an in-person visit, the surrounding care can be streamlined through virtual appointments.

---

What to Watch in 2026-2027

Regulatory Developments

• Arthrosamid FDA decision: A potential approval would introduce the first new injectable mechanism for OA in years
• CMS coverage review: No changes are currently proposed, but any modification to Medicare’s coverage determination would have enormous market impact
• State insurance mandates: Some patient advocacy groups are pushing for state-level mandates requiring coverage of viscosupplementation

Research Pipeline

• Long-term safety data: 25+ years of post-market surveillance continues to confirm the favorable safety profile of FDA-approved HA products
• Head-to-head brand comparisons: More comparative effectiveness research between HA products will help guide product selection
• Disease modification studies: The question of whether HA injections slow cartilage loss (not just manage symptoms) remains an active area of research
• GLP-1 synergies: As weight loss drugs become more widespread for OA patients, the interaction between pharmaceutical weight loss and injection outcomes may become clearer

Market Forces

• Pricing pressure: Biosimilar and generic HA products will continue to drive down per-injection costs
• Consolidation: Ongoing mergers among device and biopharmaceutical companies may reshape the brand landscape
• Direct-to-patient marketing: Expect increased patient-facing advertising as brands compete in an environment where patient preference increasingly drives product selection

---

Bottom Line: Where Things Stand

Viscosupplementation in 2026 is a treatment with strong patient demand, a solid (if debated) evidence base, stable Medicare coverage, and a fragmented private insurance landscape. The core proposition hasn’t changed: for many patients with mild to moderate knee osteoarthritis, HA injections offer meaningful pain relief and functional improvement with minimal risk.

The challenges are real. Some insurers are pulling back. Administrative hurdles are growing. The scientific debate about optimal patient selection continues.

But the fundamentals remain:

• Millions of patients benefit from viscosupplementation each year
• Medicare coverage is stable and based on established evidence
• The safety profile is excellent after 25+ years of clinical use
• New products and approaches continue to improve the treatment landscape
• The alternative — doing nothing or relying on cortisone — carries its own documented risks

For patients considering viscosupplementation, the most important steps haven’t changed: get a proper diagnosis, understand your insurance coverage, find a provider who uses imaging guidance, and set realistic expectations about outcomes.

---

Frequently Asked Questions

Is viscosupplementation still covered by Medicare in 2026?

Yes. Medicare Part B continues to cover viscosupplementation for documented knee osteoarthritis. There are no pending changes to this coverage. Patients must meet standard requirements including documented OA and failure of conservative treatment. See our complete Medicare coverage guide.

Why did BCBS Illinois stop covering gel injections?

BCBS Illinois classified viscosupplementation as “not medically necessary” based on their review of selected clinical guidelines. This decision is controversial because it contradicts substantial peer-reviewed evidence and Medicare’s coverage determination. Patients can appeal the decision or explore alternative coverage options.

What is Arthrosamid and is it available in the U.S.?

Arthrosamid is a polyacrylamide hydrogel injectable that is different from traditional hyaluronic acid. It’s approved in Europe but still under FDA review in the United States. It is not yet available for general clinical use in the U.S. Be cautious of any clinic claiming to offer it domestically outside a clinical trial.

Are single-injection gel shots as effective as multi-injection series?

Clinical evidence generally shows comparable efficacy between single-injection and multi-injection protocols for most patients. Single-injection products offer convenience. Multi-injection series may provide a higher total HA dose. Your doctor can recommend the best option based on your specific situation and insurance coverage.

Is the trend moving toward or away from viscosupplementation?

The trend is mixed. Patient demand and clinical use remain strong. Medicare coverage is stable. Some private insurers are pulling back. Research continues to support efficacy for appropriate patients. Newer products and imaging guidance are improving outcomes. Overall, viscosupplementation remains a well-established treatment option with a stable position in the OA treatment landscape.

How do I know if I’m a good candidate for gel injections?

The best candidates typically have mild to moderate knee osteoarthritis documented on X-ray, have tried conservative treatments (PT, medications) without adequate relief, and have realistic expectations. Patients with very severe arthritis (bone-on-bone) may see less benefit. A consultation with an orthopedic specialist or pain management provider can determine if you’re a good candidate.

Will insurance coverage for gel injections continue to shrink?

It’s difficult to predict. The BCBS Illinois decision raised concerns, but no additional major insurers had announced similar changes as of March 2026. Medicare coverage remains stable. Patient advocacy efforts and continued research supporting efficacy may help maintain private coverage. We’ll continue tracking coverage changes in future reports.

---

This report reflects publicly available information as of March 2026. Market valuations, coverage policies, and regulatory status may change. This article is for informational purposes only and does not constitute medical or financial advice. Always verify insurance coverage with your specific plan before proceeding with treatment.

Last reviewed: March 2026